STOCK TITAN

MannKind Corp insider sale: 18,777 MNKD shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MannKind Corporation executive reports stock sale under pre-set plan. On 11/14/2025, an officer of MannKind Corp (MNKD), serving as EVP Technical Operations, sold 18,777 shares of common stock in an open-market transaction coded as a sale. The weighted average sale price was $5.03 per share, based on individual trades between $5.00 and $5.07. After this transaction, the executive directly beneficially owned 455,211 shares of MannKind common stock. The filing notes that the sale occurred pursuant to a Rule 10b5-1 trading plan that was established on May 14, 2025, indicating the trades were made according to a pre-arranged schedule.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Singh Sanjay R

(Last) (First) (Middle)
1 CASPER STREET

(Street)
DANBURY CT 06810

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP Technical Operations
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 Par Value 11/14/2025 S(1) 18,777 D $5.03(2) 455,211 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Transaction occured pursuant to Rule 10B5-1 Plan established May 14, 2025.
2. The weighted average sales price of the reported transaction was $5.03 based on a range of prices between $5.00 and $5.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Sanjay R Singh 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MannKind Corp (MNKD) disclose in this Form 4?

The filing reports that an officer of MannKind Corp (MNKD) sold 18,777 shares of common stock in an open-market sale on 11/14/2025.

At what price were the MannKind (MNKD) shares sold in this insider trade?

The weighted average sales price was $5.03 per share, based on individual sale prices ranging between $5.00 and $5.07.

How many MannKind (MNKD) shares does the reporting person own after this transaction?

Following the reported sale, the executive beneficially owned 455,211 shares of MannKind common stock directly.

Who is the MannKind (MNKD) insider involved and what is their role?

The reporting person is an officer of MannKind Corp with the title EVP Technical Operations, as indicated in the Form 4.

Was the MannKind (MNKD) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction occurred pursuant to a Rule 10b5-1 plan that was established on May 14, 2025.

Can investors see detailed price breakdowns for the MannKind (MNKD) insider sale?

The filing explains that full information on the number of shares sold at each separate price between $5.00 and $5.07 will be provided upon request to the SEC staff, the issuer, or any security holder.
Mannkind

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Latest SEC Filings

MNKD Stock Data

1.74B
301.58M
1.66%
55.86%
5.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
DANBURY